Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Toxin-antitoxin systems and regulatory mechanisms in Mycobacterium tuberculosis.

Slayden RA, Dawson CC, Cummings JE.

Pathog Dis. 2018 Jun 1;76(4). doi: 10.1093/femspd/fty039. Review.

PMID:
29788125
2.

Biomarkers for equine joint injury and osteoarthritis.

McIlwraith CW, Kawcak CE, Frisbie DD, Little CB, Clegg PD, Peffers MJ, Karsdal MA, Ekman S, Laverty S, Slayden RA, Sandell LJ, Lohmander LS, Kraus VB.

J Orthop Res. 2018 Mar;36(3):823-831. doi: 10.1002/jor.23738. Epub 2018 Jan 24.

3.

Thermal and Photoinduced Copper-Promoted C-Se Bond Formation: Synthesis of 2-Alkyl-1,2-benzisoselenazol-3(2H)-ones and Evaluation against Mycobacterium tuberculosis.

Thanna S, Goins CM, Knudson SE, Slayden RA, Ronning DR, Sucheck SJ.

J Org Chem. 2017 Apr 7;82(7):3844-3854. doi: 10.1021/acs.joc.7b00440. Epub 2017 Mar 20.

4.

Rationalizing the Binding Kinetics for the Inhibition of the Burkholderia pseudomallei FabI1 Enoyl-ACP Reductase.

Neckles C, Eltschkner S, Cummings JE, Hirschbeck M, Daryaee F, Bommineni GR, Zhang Z, Spagnuolo L, Yu W, Davoodi S, Slayden RA, Kisker C, Tonge PJ.

Biochemistry. 2017 Apr 4;56(13):1865-1878. doi: 10.1021/acs.biochem.6b01048. Epub 2017 Mar 21.

5.

Evaluating the Contribution of Transition-State Destabilization to Changes in the Residence Time of Triazole-Based InhA Inhibitors.

Spagnuolo LA, Eltschkner S, Yu W, Daryaee F, Davoodi S, Knudson SE, Allen EK, Merino J, Pschibul A, Moree B, Thivalapill N, Truglio JJ, Salafsky J, Slayden RA, Kisker C, Tonge PJ.

J Am Chem Soc. 2017 Mar 8;139(9):3417-3429. doi: 10.1021/jacs.6b11148. Epub 2017 Feb 22.

6.

Transient In Vivo Resistance Mechanisms of Burkholderia pseudomallei to Ceftazidime and Molecular Markers for Monitoring Treatment Response.

Cummings JE, Slayden RA.

PLoS Negl Trop Dis. 2017 Jan 12;11(1):e0005209. doi: 10.1371/journal.pntd.0005209. eCollection 2017 Jan.

7.

Formulation studies of InhA inhibitors and combination therapy to improve efficacy against Mycobacterium tuberculosis.

Knudson SE, Cummings JE, Bommineni GR, Pan P, Tonge PJ, Slayden RA.

Tuberculosis (Edinb). 2016 Dec;101:8-14. doi: 10.1016/j.tube.2016.07.016. Epub 2016 Aug 3.

8.

Immune Modulation as an Effective Adjunct Post-exposure Therapeutic for B. pseudomallei.

Wilson WJ, Afzali MF, Cummings JE, Legare ME, Tjalkens RB, Allen CP, Slayden RA, Hanneman WH.

PLoS Negl Trop Dis. 2016 Oct 28;10(10):e0005065. doi: 10.1371/journal.pntd.0005065. eCollection 2016 Oct.

9.

Synthesis and evaluation of new 2-aminothiophenes against Mycobacterium tuberculosis.

Thanna S, Knudson SE, Grzegorzewicz A, Kapil S, Goins CM, Ronning DR, Jackson M, Slayden RA, Sucheck SJ.

Org Biomol Chem. 2016 Jul 7;14(25):6119-6133. doi: 10.1039/c6ob00821f. Epub 2016 Jun 2.

10.

Thiolactomycin-Based Inhibitors of Bacterial β-Ketoacyl-ACP Synthases with in Vivo Activity.

Bommineni GR, Kapilashrami K, Cummings JE, Lu Y, Knudson SE, Gu C, Walker SG, Slayden RA, Tonge PJ.

J Med Chem. 2016 Jun 9;59(11):5377-90. doi: 10.1021/acs.jmedchem.6b00236. Epub 2016 May 24.

11.

Adeno-associated virus gene therapy vector scAAVIGF-I for transduction of equine articular chondrocytes and RNA-seq analysis.

Hemphill DD, McIlwraith CW, Slayden RA, Samulski RJ, Goodrich LR.

Osteoarthritis Cartilage. 2016 May;24(5):902-11. doi: 10.1016/j.joca.2015.12.001. Epub 2015 Dec 17.

12.

Cell division inhibitors with efficacy equivalent to isoniazid in the acute murine Mycobacterium tuberculosis infection model.

Knudson SE, Awasthi D, Kumar K, Carreau A, Goullieux L, Lagrange S, Vermet H, Ojima I, Slayden RA.

J Antimicrob Chemother. 2015 Nov;70(11):3070-3. doi: 10.1093/jac/dkv226. Epub 2015 Aug 5.

13.

MadR1, a Mycobacterium tuberculosis cell cycle stress response protein that is a member of a widely conserved protein class of prokaryotic, eukaryotic and archeal origin.

Crew R, Ramirez MV, England K, Slayden RA.

Tuberculosis (Edinb). 2015 May;95(3):251-8. doi: 10.1016/j.tube.2015.03.005. Epub 2015 Mar 13.

14.

In vitro-in vivo activity relationship of substituted benzimidazole cell division inhibitors with activity against Mycobacterium tuberculosis.

Knudson SE, Kumar K, Awasthi D, Ojima I, Slayden RA.

Tuberculosis (Edinb). 2014 May;94(3):271-6. doi: 10.1016/j.tube.2014.03.007. Epub 2014 Apr 1.

15.

Rational design of broad spectrum antibacterial activity based on a clinically relevant enoyl-acyl carrier protein (ACP) reductase inhibitor.

Schiebel J, Chang A, Shah S, Lu Y, Liu L, Pan P, Hirschbeck MW, Tareilus M, Eltschkner S, Yu W, Cummings JE, Knudson SE, Bommineni GR, Walker SG, Slayden RA, Sotriffer CA, Tonge PJ, Kisker C.

J Biol Chem. 2014 Jun 6;289(23):15987-6005. doi: 10.1074/jbc.M113.532804. Epub 2014 Apr 16.

16.

A trisubstituted benzimidazole cell division inhibitor with efficacy against Mycobacterium tuberculosis.

Knudson SE, Awasthi D, Kumar K, Carreau A, Goullieux L, Lagrange S, Vermet H, Ojima I, Slayden RA.

PLoS One. 2014 Apr 15;9(4):e93953. doi: 10.1371/journal.pone.0093953. eCollection 2014.

17.

Design, synthesis and evaluation of novel 2,5,6-trisubstituted benzimidazoles targeting FtsZ as antitubercular agents.

Park B, Awasthi D, Chowdhury SR, Melief EH, Kumar K, Knudson SE, Slayden RA, Ojima I.

Bioorg Med Chem. 2014 May 1;22(9):2602-12. doi: 10.1016/j.bmc.2014.03.035. Epub 2014 Apr 1.

18.

Time-dependent diaryl ether inhibitors of InhA: structure-activity relationship studies of enzyme inhibition, antibacterial activity, and in vivo efficacy.

Pan P, Knudson SE, Bommineni GR, Li HJ, Lai CT, Liu N, Garcia-Diaz M, Simmerling C, Patil SS, Slayden RA, Tonge PJ.

ChemMedChem. 2014 Apr;9(4):776-91. doi: 10.1002/cmdc.201300429. Epub 2014 Mar 11.

19.

Substituted diphenyl ethers as a novel chemotherapeutic platform against Burkholderia pseudomallei.

Cummings JE, Beaupre AJ, Knudson SE, Liu N, Yu W, Neckles C, Wang H, Khanna A, Bommineni GR, Trunck LA, Schweizer HP, Tonge PJ, Slayden RA.

Antimicrob Agents Chemother. 2014;58(3):1646-51. doi: 10.1128/AAC.02296-13. Epub 2013 Dec 30.

20.

The Burkholderia pseudomallei enoyl-acyl carrier protein reductase FabI1 is essential for in vivo growth and is the target of a novel chemotherapeutic with efficacy.

Cummings JE, Kingry LC, Rholl DA, Schweizer HP, Tonge PJ, Slayden RA.

Antimicrob Agents Chemother. 2014;58(2):931-5. doi: 10.1128/AAC.00176-13. Epub 2013 Nov 25.

21.

Iterative feature removal yields highly discriminative pathways.

O'Hara S, Wang K, Slayden RA, Schenkel AR, Huber G, O'Hern CS, Shattuck MD, Kirby M.

BMC Genomics. 2013 Nov 25;14:832. doi: 10.1186/1471-2164-14-832.

22.

SAR studies on trisubstituted benzimidazoles as inhibitors of Mtb FtsZ for the development of novel antitubercular agents.

Awasthi D, Kumar K, Knudson SE, Slayden RA, Ojima I.

J Med Chem. 2013 Dec 12;56(23):9756-70. doi: 10.1021/jm401468w. Epub 2013 Nov 23.

23.

MazF6 toxin of Mycobacterium tuberculosis demonstrates antitoxin specificity and is coupled to regulation of cell growth by a Soj-like protein.

Ramirez MV, Dawson CC, Crew R, England K, Slayden RA.

BMC Microbiol. 2013 Oct 31;13:240. doi: 10.1186/1471-2180-13-240.

24.

Benzimidazole-based antibacterial agents against Francisella tularensis.

Kumar K, Awasthi D, Lee SY, Cummings JE, Knudson SE, Slayden RA, Ojima I.

Bioorg Med Chem. 2013 Jun 1;21(11):3318-26. doi: 10.1016/j.bmc.2013.02.059. Epub 2013 Apr 3.

25.

The ly49 gene family. A brief guide to the nomenclature, genetics, and role in intracellular infection.

Schenkel AR, Kingry LC, Slayden RA.

Front Immunol. 2013 Apr 16;4:90. doi: 10.3389/fimmu.2013.00090. eCollection 2013.

26.

Updating and curating metabolic pathways of TB.

Slayden RA, Jackson M, Zucker J, Ramirez MV, Dawson CC, Crew R, Sampson NS, Thomas ST, Jamshidi N, Sisk P, Caspi R, Crick DC, McNeil MR, Pavelka MS, Niederweis M, Siroy A, Dona V, McFadden J, Boshoff H, Lew JM.

Tuberculosis (Edinb). 2013 Jan;93(1):47-59. doi: 10.1016/j.tube.2012.11.001. Epub 2013 Feb 1. Review.

27.

The Francisella tularensis FabI enoyl-acyl carrier protein reductase gene is essential to bacterial viability and is expressed during infection.

Kingry LC, Cummings JE, Brookman KW, Bommineni GR, Tonge PJ, Slayden RA.

J Bacteriol. 2013 Jan;195(2):351-8. doi: 10.1128/JB.01957-12. Epub 2012 Nov 9.

28.

CoA Adducts of 4-Oxo-4-Phenylbut-2-enoates: Inhibitors of MenB from the M. tuberculosis Menaquinone Biosynthesis Pathway.

Li X, Liu N, Zhang H, Knudson SE, Li HJ, Lai CT, Simmerling C, Slayden RA, Tonge PJ.

ACS Med Chem Lett. 2011 Nov 10;2(11):818-823.

30.

Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei.

Liu N, Cummings JE, England K, Slayden RA, Tonge PJ.

J Antimicrob Chemother. 2011 Mar;66(3):564-73. doi: 10.1093/jac/dkq509. Epub 2011 Jan 22.

31.

Discovery of anti-TB agents that target the cell-division protein FtsZ.

Kumar K, Awasthi D, Berger WT, Tonge PJ, Slayden RA, Ojima I.

Future Med Chem. 2010 Aug;2(8):1305-23. doi: 10.4155/fmc.10.220. Review.

32.

A specific interaction of small molecule entry inhibitors with the envelope glycoprotein complex of the Junín hemorrhagic fever arenavirus.

Thomas CJ, Casquilho-Gray HE, York J, DeCamp DL, Dai D, Petrilli EB, Boger DL, Slayden RA, Amberg SM, Sprang SR, Nunberg JH.

J Biol Chem. 2011 Feb 25;286(8):6192-200. doi: 10.1074/jbc.M110.196428. Epub 2010 Dec 15.

33.

Novel trisubstituted benzimidazoles, targeting Mtb FtsZ, as a new class of antitubercular agents.

Kumar K, Awasthi D, Lee SY, Zanardi I, Ruzsicska B, Knudson S, Tonge PJ, Slayden RA, Ojima I.

J Med Chem. 2011 Jan 13;54(1):374-81. doi: 10.1021/jm1012006. Epub 2010 Dec 2.

34.

Genetic identification of unique immunological responses in mice infected with virulent and attenuated Francisella tularensis.

Kingry LC, Troyer RM, Marlenee NL, Bielefeldt-Ohmann H, Bowen RA, Schenkel AR, Dow SW, Slayden RA.

Microbes Infect. 2011 Mar;13(3):261-75. doi: 10.1016/j.micinf.2010.10.022. Epub 2010 Nov 9.

35.

Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

Li X, Liu N, Zhang H, Knudson SE, Slayden RA, Tonge PJ.

Bioorg Med Chem Lett. 2010 Nov 1;20(21):6306-9. doi: 10.1016/j.bmcl.2010.08.076. Epub 2010 Aug 21.

36.

An optical waveguide array biosensor for serology - biomed 2010.

Yan R, Lynn NS, Kingry LC, Slayden RA, Dandy DS, Lear KL.

Biomed Sci Instrum. 2010;46:45-50.

PMID:
20467070
37.

Substituted diphenyl ethers as a broad-spectrum platform for the development of chemotherapeutics for the treatment of tularaemia.

England K, am Ende C, Lu H, Sullivan TJ, Marlenee NL, Bowen RA, Knudson SE, Knudson DL, Tonge PJ, Slayden RA.

J Antimicrob Chemother. 2009 Nov;64(5):1052-61. doi: 10.1093/jac/dkp307. Epub 2009 Sep 4.

38.

Implications of high level pseudogene transcription in Mycobacterium leprae.

Williams DL, Slayden RA, Amin A, Martinez AN, Pittman TL, Mira A, Mitra A, Nagaraja V, Morrison NE, Moraes M, Gillis TP.

BMC Genomics. 2009 Aug 25;10:397. doi: 10.1186/1471-2164-10-397.

39.

Discovery, synthesis, and biological evaluation of piperidinol analogs with anti-tuberculosis activity.

Sun D, Scherman MS, Jones V, Hurdle JG, Woolhiser LK, Knudson SE, Lenaerts AJ, Slayden RA, McNeil MR, Lee RE.

Bioorg Med Chem. 2009 May 15;17(10):3588-94. doi: 10.1016/j.bmc.2009.04.005. Epub 2009 Apr 9.

40.

Menaquinone synthesis is critical for maintaining mycobacterial viability during exponential growth and recovery from non-replicating persistence.

Dhiman RK, Mahapatra S, Slayden RA, Boyne ME, Lenaerts A, Hinshaw JC, Angala SK, Chatterjee D, Biswas K, Narayanasamy P, Kurosu M, Crick DC.

Mol Microbiol. 2009 Apr;72(1):85-97. doi: 10.1111/j.1365-2958.2009.06625.x. Epub 2009 Feb 11.

41.

Slow-onset inhibition of the FabI enoyl reductase from francisella tularensis: residence time and in vivo activity.

Lu H, England K, am Ende C, Truglio JJ, Luckner S, Reddy BG, Marlenee NL, Knudson SE, Knudson DL, Bowen RA, Kisker C, Slayden RA, Tonge PJ.

ACS Chem Biol. 2009 Mar 20;4(3):221-31. doi: 10.1021/cb800306y.

42.

Morphological features and signature gene response elicited by inactivation of FtsI in Mycobacterium tuberculosis.

Slayden RA, Belisle JT.

J Antimicrob Chemother. 2009 Mar;63(3):451-7. doi: 10.1093/jac/dkn507. Epub 2008 Dec 24.

43.

Immune response to Mycobacterium tuberculosis and identification of molecular markers of disease.

Gonzalez-Juarrero M, Kingry LC, Ordway DJ, Henao-Tamayo M, Harton M, Basaraba RJ, Hanneman WH, Orme IM, Slayden RA.

Am J Respir Cell Mol Biol. 2009 Apr;40(4):398-409. doi: 10.1165/rcmb.2008-0248OC. Epub 2008 Sep 11.

44.

Characterizing septum inhibition in Mycobacterium tuberculosis for novel drug discovery.

Respicio L, Nair PA, Huang Q, Anil B, Tracz S, Truglio JJ, Kisker C, Raleigh DP, Ojima I, Knudson DL, Tonge PJ, Slayden RA.

Tuberculosis (Edinb). 2008 Sep;88(5):420-9. doi: 10.1016/j.tube.2008.03.001. Epub 2008 May 13.

PMID:
18479968
45.

Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.

am Ende CW, Knudson SE, Liu N, Childs J, Sullivan TJ, Boyne M, Xu H, Gegina Y, Knudson DL, Johnson F, Peloquin CA, Slayden RA, Tonge PJ.

Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. doi: 10.1016/j.bmcl.2008.04.038. Epub 2008 Apr 18.

46.

Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against Mycobacterium tuberculosis: evaluation of A-ring-modified diphenyl ethers as high-affinity InhA inhibitors.

Boyne ME, Sullivan TJ, amEnde CW, Lu H, Gruppo V, Heaslip D, Amin AG, Chatterjee D, Lenaerts A, Tonge PJ, Slayden RA.

Antimicrob Agents Chemother. 2007 Oct;51(10):3562-7. Epub 2007 Jul 30.

47.

FtsZ: a novel target for tuberculosis drug discovery.

Huang Q, Tonge PJ, Slayden RA, Kirikae T, Ojima I.

Curr Top Med Chem. 2007;7(5):527-43. Review.

PMID:
17346197
48.

Development of modern InhA inhibitors to combat drug resistant strains of Mycobacterium tuberculosis.

Tonge PJ, Kisker C, Slayden RA.

Curr Top Med Chem. 2007;7(5):489-98. Review.

PMID:
17346194
49.

High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis.

Sullivan TJ, Truglio JJ, Boyne ME, Novichenok P, Zhang X, Stratton CF, Li HJ, Kaur T, Amin A, Johnson F, Slayden RA, Kisker C, Tonge PJ.

ACS Chem Biol. 2006 Feb 17;1(1):43-53.

PMID:
17163639
50.

Use of protein microarrays to define the humoral immune response in leprosy patients and identification of disease-state-specific antigenic profiles.

Groathouse NA, Amin A, Marques MA, Spencer JS, Gelber R, Knudson DL, Belisle JT, Brennan PJ, Slayden RA.

Infect Immun. 2006 Nov;74(11):6458-66. Epub 2006 Sep 11.

Supplemental Content

Loading ...
Support Center